McKerracher

BioAxone BioSciences is a clinical-stage biotechnology company focused on developing innovative therapies for neuroregeneration and vascular diseases of the central nervous system. Founded by Dr. Lisa McKerracher, a pioneer in Rho GTPase research, the company leverages its expertise in axon regeneration to target conditions such as spinal cord injury and cerebral cavernous malformations. Its lead program, Cethrin (VX-210), is a recombinant protein Rho inhibitor that was out-licensed to Vertex Pharmaceuticals for the treatment of acute spinal cord injury. BioAxone continues to advance a pipeline of small molecules and biologics, including BA-1049, a ROCK2 inhibitor for cerebral cavernous malformations, and BA-434, a PTEN inhibitor for neural repair. The company's approach focuses on overcoming the inhibitory environment of the CNS to promote functional recovery after injury or disease.